eazyplex® MRSA



eazyplex® MRSA


Lyophilized

Ready to use

No DNA extraction

Fast

eazyplex® MRSA     

We are all in the same boat!

MRSA can affect anyone!


Staphylococcus aureus is one of the most important pathogens for nosocomial infections. In its resistant form as MRSA, due to the difficulty of treating it, it constitutes a significant risk factor for affected patients and occurs in hospitals all over the world. But there are also forms of MRSA that are completely independent of hospitals and that are often also resistant to the antibiotic fusidic acid. These germs are known as CA-MRSA (community-acquired MRSA) and also have a special pathogenicity factor (Panton-Valentine-leukocidine, encoded by the lukS-lukF gene).

eazyplex® MRSA

eazyplex® MRSA 

With the eazyplex® MRSA, there is clear detection of: - S. aureus - mecA - mecC - S. epidermidis

The two integrated controls help avoid false negative results.

Download Flyer Deutsch Download Flyer English

eazyplex® MRSAplus

The eazyplex® MRSAplus provides clear evidence of:

- S. aureus

- mecha

- mecC and

- PVL-Toxin


Download Flyer Deutsch Download Flyer English

Details:

With the combination of the two test kits eazyplex® MRSA and eazyplex® MRSAplus you have the complete solution for your MRSA diagnostics. Whether as an examination directly from the screening swabs in 20 minutes or as a detection from positive blood cultures or from agar plates in 15 minutes, you will receive the result quickly and clearly without DNA extraction.

Staphylococcus aureus is one of the most prominent pathogens of nosocomial infections, while other representatives of the genus Staphylococcus are apathogenic colonizers of human skin. Staphylococci are responsible for a number of diseases. In addition to staphylococcal osteomyelitis, sepsis, meningitis, pneumonia and prostatitis, they can also be implicated in liver disease, tuberculosis and diseases of the genitourinary system. Staphylococci can occur in most types of nosocomial infections. The increasing occurrence of multi-resistant pathogens is of particular importance. Methicillin-resistant S. aureus (MRSA) in particular should be mentioned here. Due to the difficulty of treating it, MRSA forms a significant risk factor for affected patients and occurs in hospitals all over the world. In 1998, the first cases of so-called cMRSA / CA-MRSA (community-acquired MRSA) were observed in the USA, which occur completely independently of hospitals. In addition to the genetic methicillin resistance, they also very often show resistance to the antibiotic fusidic acid. cMRSA strains also have a special pathogenicity factor (Panton-Valentine-Leukozidin, encoded by the lukS-lukF gene). CA-MRSA have the special ability to form multiple, recurrent deep abscesses, as well as to cause pneumonia with a necrotizing, often fatal course.

In 2011, a new variant of a gene causing methicillin resistance was discovered in S. aureus isolates from animal stocks, which was officially named mecC (originally mecA LGA251) at the beginning of 2012. This gene shows about 70% sequence homology to mecA and is most likely originally from Macrococcus caseolyticus. This resistance can neither be detected with conventional latex agglutination tests nor with a mecA-specific PCR.

Share by: